The Trump administration has reclassified medical marijuana from a Schedule I to a Schedule III drug, easing federal restrictions and aligning it with substances like Tylenol with codeine. This change, announced by Acting Attorney General Todd Blanche, aims to facilitate research on marijuana’s safety and efficacy, potentially improving patient care and providing doctors with more reliable information. Previously, marijuana was classified alongside drugs like heroin and LSD, which are considered to have no accepted medical use and a high potential for abuse. The rescheduling acknowledges state regulations on medical marijuana and applies only to FDA-approved products and those regulated under state medical licenses. This shift could reduce the tax burden on cannabis businesses and simplify research processes. However, anti-legalization groups argue that marijuana remains dangerous and should not be legalized indirectly. The DEA plans to hold hearings on broader marijuana rescheduling.
QUESTION: How might the reclassification of medical marijuana impact future research and public perception of the drug?
Trump administration eases rules on some marijuana categories. Here’s what to know
